The frontotemporal dementia market size has grown strongly in recent years. It will grow from $3.25 billion in 2025 to $3.53 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to improved clinical recognition of frontotemporal dementia, expansion of specialized neurology clinics, increased availability of neuroimaging technologies, rising awareness among healthcare professionals, development of standardized diagnostic criteria.
The frontotemporal dementia market size is expected to see strong growth in the next few years. It will grow to $4.99 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising adoption of precision medicine approaches, expansion of digital health tools for cognitive assessment, growing focus on disease-modifying therapies, increasing caregiver support and management programs. Major trends in the forecast period include increasing use of advanced neuroimaging diagnostics, rising adoption of genetic and biomarker testing, growing focus on early and accurate disease differentiation, expansion of multidisciplinary care models, enhanced integration of digital cognitive assessment tools.
The expansion of precision medicine is expected to propel the growth of the frontotemporal dementia market going forward. Precision medicine involves tailoring medical care based on an individual’s biological characteristics, genetics, and lifestyle factors. Adoption of precision medicine is increasing due to advancements in genomics and biotechnology, which enable more accurate identification of disease mechanisms and the development of targeted therapies, leading to improved patient outcomes. Precision medicine supports frontotemporal dementia by enabling earlier and more accurate diagnosis through genetic testing and biomarker analysis, as well as guiding the development of therapies that target specific molecular pathways involved in disease progression, thereby improving treatment effectiveness and slowing disease advancement. For instance, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022, including therapies for cancer and other disease areas. Therefore, the growing adoption of precision medicine is driving the growth of the frontotemporal dementia market.
Key companies operating in the frontotemporal dementia market are focusing on developing innovative solutions such as monoclonal antibody therapy to slow disease progression and address underlying pathological mechanisms. Monoclonal antibody therapy refers to a treatment approach that uses laboratory-made antibodies designed to target specific proteins or cells in the body, helping to treat diseases by blocking, neutralizing, or marking harmful cells for destruction. For example, in February 2024, Alector Inc., a US-based clinical-stage biotechnology company, partnered with GSK Plc., a UK-based biopharma company, and received FDA Breakthrough Therapy Designation for latozinemab (AL001), designed to treat frontotemporal dementia due to progranulin gene mutation (FTD-GRN) by inhibiting the sortilin receptor and elevating progranulin (PGRN) levels in the brain to address lysosomal dysfunction and neurodegeneration. Phase 2 trials demonstrated safe, sustained PGRN increases of over two-fold in plasma and cerebrospinal fluid, with observed trends toward slowing clinical disease progression.
In June 2024, Eli Lilly and Company, a US-based pharmaceutical company, entered into an exclusive license and research collaboration with QurAlis to develop splice-switching antisense oligonucleotides targeting UNC13A in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Through this partnership, the companies aim to develop and commercialize QRL-204 for FTD and ALS, while also collaborating on next-generation UNC13A-targeting therapies, expanding Lilly’s neurodegeneration portfolio and accelerating precision medicine approaches for genetically defined forms of frontotemporal dementia. QurAlis, Inc. is a US-based clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including FTD.
Major companies operating in the frontotemporal dementia market are Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Alector Inc., Denali Therapeutics Inc., Sangamo Therapeutics Inc., QurAlis Inc., TauRx Pharmaceuticals Ltd., AC Immune SA, AviadoBio Ltd., Passage Bio Inc., Muna Therapeutics Inc., Neurimmune Therapeutics Inc., Coya Therapeutics Inc., Aquinnah Pharmaceuticals Inc., Asceneuron SA, CAMP4 Therapeutics Inc., Libra Therapeutics Inc., SOLA Biosciences Inc., Transposon Therapeutics Inc.
Tariffs are influencing the frontotemporal dementia market by increasing costs of imported diagnostic imaging equipment, genetic testing kits, laboratory reagents, and digital health technologies used in disease assessment and management. Healthcare systems in North America and Europe are most affected due to dependence on imported medical devices and diagnostics, while Asia-Pacific faces higher costs for specialized testing equipment. These tariffs are increasing diagnostic expenses and slowing technology upgrades. However, they are also encouraging regional manufacturing of diagnostic tools, localized laboratory services, and investment in digital-first dementia assessment solutions.
The frontotemporal dementia market research report is one of a series of new reports that provides frontotemporal dementia market statistics, including frontotemporal dementia industry global market size, regional shares, competitors with a frontotemporal dementia market share, detailed frontotemporal dementia market segments, market trends and opportunities, and any further data you may need to thrive in the frontotemporal dementia industry. This frontotemporal dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Frontotemporal dementia is a set of neurodegenerative conditions marked by progressive deterioration of the frontal and temporal lobes of the brain. It results in alterations in behavior, personality, language, and executive functions. The disorder generally worsens over time and significantly affects cognitive and social capabilities.
The primary disease types of frontotemporal dementia include behavioral variant frontotemporal dementia, primary progressive aphasia, and frontotemporal dementia with motor neuron disease. Behavioral variant frontotemporal dementia refers to a form of dementia characterized by significant changes in personality, behavior, and social conduct. These conditions are treated with drug classes such as cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, antidepressants, and antipsychotics. The diagnostic methods include clinical evaluation, neuroimaging, and genetic testing. The treatment approaches include symptom management, medications, and speech and occupational therapy, and the end users are hospitals, specialty clinics, and long-term care facilities.
The frontotemporal dementia market includes revenues earned by entities through patient diagnosis and cognitive assessments, genetic and biomarker testing, neurological consultations, clinical management and treatment planning, and caregiver support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The frontotemporal dementia market size is expected to see strong growth in the next few years. It will grow to $4.99 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising adoption of precision medicine approaches, expansion of digital health tools for cognitive assessment, growing focus on disease-modifying therapies, increasing caregiver support and management programs. Major trends in the forecast period include increasing use of advanced neuroimaging diagnostics, rising adoption of genetic and biomarker testing, growing focus on early and accurate disease differentiation, expansion of multidisciplinary care models, enhanced integration of digital cognitive assessment tools.
The expansion of precision medicine is expected to propel the growth of the frontotemporal dementia market going forward. Precision medicine involves tailoring medical care based on an individual’s biological characteristics, genetics, and lifestyle factors. Adoption of precision medicine is increasing due to advancements in genomics and biotechnology, which enable more accurate identification of disease mechanisms and the development of targeted therapies, leading to improved patient outcomes. Precision medicine supports frontotemporal dementia by enabling earlier and more accurate diagnosis through genetic testing and biomarker analysis, as well as guiding the development of therapies that target specific molecular pathways involved in disease progression, thereby improving treatment effectiveness and slowing disease advancement. For instance, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022, including therapies for cancer and other disease areas. Therefore, the growing adoption of precision medicine is driving the growth of the frontotemporal dementia market.
Key companies operating in the frontotemporal dementia market are focusing on developing innovative solutions such as monoclonal antibody therapy to slow disease progression and address underlying pathological mechanisms. Monoclonal antibody therapy refers to a treatment approach that uses laboratory-made antibodies designed to target specific proteins or cells in the body, helping to treat diseases by blocking, neutralizing, or marking harmful cells for destruction. For example, in February 2024, Alector Inc., a US-based clinical-stage biotechnology company, partnered with GSK Plc., a UK-based biopharma company, and received FDA Breakthrough Therapy Designation for latozinemab (AL001), designed to treat frontotemporal dementia due to progranulin gene mutation (FTD-GRN) by inhibiting the sortilin receptor and elevating progranulin (PGRN) levels in the brain to address lysosomal dysfunction and neurodegeneration. Phase 2 trials demonstrated safe, sustained PGRN increases of over two-fold in plasma and cerebrospinal fluid, with observed trends toward slowing clinical disease progression.
In June 2024, Eli Lilly and Company, a US-based pharmaceutical company, entered into an exclusive license and research collaboration with QurAlis to develop splice-switching antisense oligonucleotides targeting UNC13A in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Through this partnership, the companies aim to develop and commercialize QRL-204 for FTD and ALS, while also collaborating on next-generation UNC13A-targeting therapies, expanding Lilly’s neurodegeneration portfolio and accelerating precision medicine approaches for genetically defined forms of frontotemporal dementia. QurAlis, Inc. is a US-based clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including FTD.
Major companies operating in the frontotemporal dementia market are Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Alector Inc., Denali Therapeutics Inc., Sangamo Therapeutics Inc., QurAlis Inc., TauRx Pharmaceuticals Ltd., AC Immune SA, AviadoBio Ltd., Passage Bio Inc., Muna Therapeutics Inc., Neurimmune Therapeutics Inc., Coya Therapeutics Inc., Aquinnah Pharmaceuticals Inc., Asceneuron SA, CAMP4 Therapeutics Inc., Libra Therapeutics Inc., SOLA Biosciences Inc., Transposon Therapeutics Inc.
Tariffs are influencing the frontotemporal dementia market by increasing costs of imported diagnostic imaging equipment, genetic testing kits, laboratory reagents, and digital health technologies used in disease assessment and management. Healthcare systems in North America and Europe are most affected due to dependence on imported medical devices and diagnostics, while Asia-Pacific faces higher costs for specialized testing equipment. These tariffs are increasing diagnostic expenses and slowing technology upgrades. However, they are also encouraging regional manufacturing of diagnostic tools, localized laboratory services, and investment in digital-first dementia assessment solutions.
The frontotemporal dementia market research report is one of a series of new reports that provides frontotemporal dementia market statistics, including frontotemporal dementia industry global market size, regional shares, competitors with a frontotemporal dementia market share, detailed frontotemporal dementia market segments, market trends and opportunities, and any further data you may need to thrive in the frontotemporal dementia industry. This frontotemporal dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Frontotemporal dementia is a set of neurodegenerative conditions marked by progressive deterioration of the frontal and temporal lobes of the brain. It results in alterations in behavior, personality, language, and executive functions. The disorder generally worsens over time and significantly affects cognitive and social capabilities.
The primary disease types of frontotemporal dementia include behavioral variant frontotemporal dementia, primary progressive aphasia, and frontotemporal dementia with motor neuron disease. Behavioral variant frontotemporal dementia refers to a form of dementia characterized by significant changes in personality, behavior, and social conduct. These conditions are treated with drug classes such as cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, antidepressants, and antipsychotics. The diagnostic methods include clinical evaluation, neuroimaging, and genetic testing. The treatment approaches include symptom management, medications, and speech and occupational therapy, and the end users are hospitals, specialty clinics, and long-term care facilities.
The frontotemporal dementia market includes revenues earned by entities through patient diagnosis and cognitive assessments, genetic and biomarker testing, neurological consultations, clinical management and treatment planning, and caregiver support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Frontotemporal Dementia Market Characteristics
3. Frontotemporal Dementia Market Supply Chain Analysis
4. Global Frontotemporal Dementia Market Trends and Strategies
5. Frontotemporal Dementia Market Analysis Of End Use Industries
7. Global Frontotemporal Dementia Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Frontotemporal Dementia Total Addressable Market (TAM) Analysis for the Market
9. Frontotemporal Dementia Market Segmentation
10. Frontotemporal Dementia Market Regional and Country Analysis
11. Asia-Pacific Frontotemporal Dementia Market
12. China Frontotemporal Dementia Market
13. India Frontotemporal Dementia Market
14. Japan Frontotemporal Dementia Market
15. Australia Frontotemporal Dementia Market
16. Indonesia Frontotemporal Dementia Market
17. South Korea Frontotemporal Dementia Market
18. Taiwan Frontotemporal Dementia Market
19. South East Asia Frontotemporal Dementia Market
20. Western Europe Frontotemporal Dementia Market
21. UK Frontotemporal Dementia Market
22. Germany Frontotemporal Dementia Market
23. France Frontotemporal Dementia Market
24. Italy Frontotemporal Dementia Market
25. Spain Frontotemporal Dementia Market
26. Eastern Europe Frontotemporal Dementia Market
27. Russia Frontotemporal Dementia Market
28. North America Frontotemporal Dementia Market
29. USA Frontotemporal Dementia Market
30. Canada Frontotemporal Dementia Market
31. South America Frontotemporal Dementia Market
32. Brazil Frontotemporal Dementia Market
33. Middle East Frontotemporal Dementia Market
34. Africa Frontotemporal Dementia Market
36. Frontotemporal Dementia Market Competitive Landscape and Company Profiles
37. Frontotemporal Dementia Market Other Major and Innovative Companies
41. Frontotemporal Dementia Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Frontotemporal Dementia Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses frontotemporal dementia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for frontotemporal dementia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The frontotemporal dementia market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Behavioral Variant Frontotemporal Dementia (bvFTD); Primary Progressive Aphasia (PPA); Frontotemporal Dementia With Motor Neuron Disease (FTD-MND)2) By Drug Class: Cholinesterase Inhibitors; N-Methyl-D-Aspartate (NMDA) Receptor Antagonists; Antidepressants; Antipsychotics
3) By Diagnostic Methods: Clinical Evaluation; Neuroimaging; Genetic Testing
4) By Treatment Approach: Symptom Management; Medications; Speech and Occupational Therapy
5) By End User: Hospitals; Specialty Clinics; Long-Term Care Facilities
Subsegments:
1) By Behavioral Variant Frontotemporal Dementia (bvFTD): Disinhibited Type; Apathetic Type; Stereotypic Type; Hyperorality Type2) By Primary Progressive Aphasia (PPA): Nonfluent Variant; Semantic Variant; Logopenic Variant
3) By Frontotemporal Dementia With Motor Neuron Disease (FTD-MND): Amyotrophic Lateral Sclerosis Associated; Progressive Muscular Atrophy Associated; Primary Lateral Sclerosis Associated
Companies Mentioned: Novartis AG; Eli Lilly and Company; Siemens Healthineers AG; Alector Inc.; Denali Therapeutics Inc.; Sangamo Therapeutics Inc.; QurAlis Inc.; TauRx Pharmaceuticals Ltd.; AC Immune SA; AviadoBio Ltd.; Passage Bio Inc.; Muna Therapeutics Inc.; Neurimmune Therapeutics Inc.; Coya Therapeutics Inc.; Aquinnah Pharmaceuticals Inc.; Asceneuron SA; CAMP4 Therapeutics Inc.; Libra Therapeutics Inc.; SOLA Biosciences Inc.; Transposon Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Frontotemporal Dementia market report include:- Novartis AG
- Eli Lilly and Company
- Siemens Healthineers AG
- Alector Inc.
- Denali Therapeutics Inc.
- Sangamo Therapeutics Inc.
- QurAlis Inc.
- TauRx Pharmaceuticals Ltd.
- AC Immune SA
- AviadoBio Ltd.
- Passage Bio Inc.
- Muna Therapeutics Inc.
- Neurimmune Therapeutics Inc.
- Coya Therapeutics Inc.
- Aquinnah Pharmaceuticals Inc.
- Asceneuron SA
- CAMP4 Therapeutics Inc.
- Libra Therapeutics Inc.
- SOLA Biosciences Inc.
- Transposon Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.53 Billion |
| Forecasted Market Value ( USD | $ 4.99 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
